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The state of immunological unresponsiveness  ~ is  a  widely studied but little 
understood  phenomenon.  In  the  majority  of  cases,  the  tolerogenic  antigen 
(tolerogen) is a complex molecule with many determinants, and is often capable 
of inducing immunity as well as tolerance (1). This is obviously the case with 
such antigens as heterologous erythrocytes, where the timing and duration of 
treatment determine the tolerogenicity of the antigen (2). With serum proteins, 
both immunogenic and tolerogenic forms are often present together (3, 4), fur- 
ther complicating matters.  Even with potentially tolerogenic preparations  of 
such materials,  the induction of unresponsiveness depends upon the mode of 
administration.  ~ The use of tolerogens with a single determinant would greatly 
simplify the investigation of the immune system as a whole and aid in the under- 
standing of the cellular basis of immunological tolerance. 
Havas (5) and Borel (6) have produced tolerance to a hapten by treatment of 
mice with haptenated serum proteins and Feldman  (7)  has induced tolerance 
to a  hapten by using haptenated flagellin. We describe here and characterize 
the induction of tolerance by the injection of free hapten (8). This method has 
been investigated in terms of cell-mediated immunity and tolerance (9). While 
utilizing a hapten, this method of tolerization dispenses with the complication 
of large and complex carrier molecules. Use of the free hapten as a  tolerogen 
has provided a simple method for the studv of tolerance induction, maintenance, 
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1  The terms unresponsiveness and tolerance will  be used interchangeably. 
2 Incorporated into incomplete Freund's adjuvant, soluble human gamma globulin (HGG)  z 
induces immunity in adult BDF1  mice,  while inducing tolerance when given in the soluble 
fluid form (unpublished observations). 
3 Abbreviations used in this paper: B  cell,  thymus independent bone marrow-derived anti- 
gen-sensitive cells; BSS,  balanced salt solution; HA,  hemagglutination titer; HGG,  human 
gamma glohulin; HRBC, horse erythrocytes; ME,  2-mercaptoethanol; PFC, plaque-forming 
cells; SRBC, sheep erythrocytes; T  cells,  thymus-derived antigen-reactive cells; 1,3,5 TNB, 
1,3,5-trinitrobenzene;  TNBS,  trinitrobenzene  sulfonic  acid ;  TNP,  2,4,6-trinitrophenyl; 
TNP-glycine, u initrophenyl glycine. 
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and termination in both the whole animal and at the cellular level. It has allowed 
us to investigate tolerance  induction in B  and T  cells  4 as well  as  a  possible T 
celt inhibitory substance in tolerance  (10). 
Materials and Methods 
Mice.--BDF1 [(C57BL/6 X DBA/2)F1] mice were from our breeding colony using breeding 
stocks obtained from the Jackson Laboratory, Bar Harbor, Maine, and were used at 8-12 wk 
of age. Mice were housed five to a cage and were maintained on Wayne Lab Blox (Allied Mills, 
Inc., Chicago, Ill.) and chlorinated (11 ppm) and acidified (pH 2.8) watel ad lib. (11). Female 
mice were used unless otherwise noted. In individual experiments, all mice were generally born 
within the same 1 wk span. 
Antigen.--Sheep  erythrocytes  (SRBC)  from  the  same  animal  and  horse  erythrocytes 
(HRBC)  were obtained in Alsever's solution from the Colorado Serum Company,  Denver, 
Colo.  SRBC  heavily conjugated with 2,4,6-trlnitrophenyl  (TNP-SRBC)  were utilized for 
immunization to the TNP hapten, and were prepared essentially by the method of Kettman 
and Dutton (12). In all cases TNP-SRBC were used immediately after preparation because of 
the high degree of instability. Lightly conjugated HRBC and SRBC were prepared essentially 
by the method of Rittenberg and Pratt (13). Lightly conjugated TNP-RBC were stable for at 
least 4  days. The standard immunizing dose for both primary and secondary response chal- 
lenges of SRBC and TNP-SRBC was 2  )K  10  s erythrocytes (0.1 ml of 10% erythrocytes by 
volume in balanced salt solution [BSS] [14]) injected intraperitoneally. 
Tolerogen.--Trinitrobenzene sulfonic acid (TN-BS; Eastman Kodak Co., Rochester, N. Y.) 
was prepared for injection by dissolving 100 nag in  10 ml of 0.15  M  NaCl plus 0.029  g of 
NaHCO3.  Each injection consisted of 0.5 ml of TN]3S solution (5 mg of TNBS). Injections 
were intraperitoneal. In all cases where concentrations of TNBS other than 5 mg in 0.5 ml of 
saline were used, the amount and concentration of NaHCO~ were altered appropriately. 
Tolerogen Analogues.--Trinitrophenyl glycine  (TNP-glycine;  Sigma  Chemical  Co.,  St. 
Louis, Mo.) was prepared for injection by dissolving 34.0 mg of TNP-glycine plus 0.014 g of 
NaHCO3 in 10 ml of 0.15 M NaCl. Each injection consisted of 1.0 ml of TNP-glycine solution 
(containing 3.4 mg of TNP-glycine), an amount that was equimolar in the TNP moiety with 
the standard 5 mg dose of TNBS.  1,3,5-trinitrobenzene (1,3,5-TNB; Eastman Kodak Co.) 
was prepared for injection by dissolving 20.7 mg of 1,3,5-TNB in 5 mi of 0.15 M  NaC1 that 
was 1% in Na2SO3 to aid in dissolving the material. Individual injections consisted of 0.5 ml 
of 1,3,5-TNB solution (containing 1.88 mg of 1,3,5-TNB), an amount that was equimolar in 
the TNP. moiety with the standard 5 mg dose of TNBS. 1,3,5-TNB was obtained with water 
added. In calculations, 10% water was arbitrarily chosen as the degree of dilution. 
Assay of Plaque-Forming Cells.--Antibody-forming cells  were  19S  plaque-forming cells 
(PFC) determined by the slide modification of the Jerne hemolytic plaque technique (15). PFC 
to TNP were determined by utilizing lightly conjugated TNP-HRBC.  Horse cells exhibit less 
than 1% cross-reactivity with SRBC in the mouse. In our assay system, fewer than 1% of the 
TNP-HRBC PFC can be attributed to HRBC-directed PFC (unpublished observations) and 
PFC directed against TNP are not corrected for HRBC-directed PFC. PFC in each individual 
spleen to both the hapten and carrier were always determined at the same time. Indirect (7S, 
IgG) PFC were detected by using guinea pig complement (Hyland Laboratories, Los Angeles, 
Calif.) that was 1:200 in rabbit anti-mouse IgG (16,  17). The number of indirect (facilitated) 
PFC recorded is the difference between the direct unfaci]itated PFC count and that revealed 
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by using the amplifying antiserum. Primary response assays were conducted on day 5  after 
the injection of immunogen (unless otherwise indicated), while secondary response assays were 
conducted on day 4 after the second challenge with antigen. 
Sen~m Collection. -Mice were bled from the lateral tail vein, and the separated serum stored 
at  --15°C.  Freezing was found to have no effect upon the 2-mercaptoethanol (ME)-resistant 
titer. 
Serum T.itralions.  Serum titrations were  performed  with a Takatsy microtiter  apparatus 
(Cooke Engineering Co., Alexandria, Va.). Suspensions of thrice washed indicator erythrocytes 
(SRBC,  HRBC,  or lightly conjugated TNP-HRBC)  1.0%  by volume in BSS were used. In 
all serum titration assays of the anti-TNP response, all sera were assayed against SRBC, TNP- 
HRBC,  and HRBC.  There was generally no detectable  hemagglutination (HA)  titer  to  the 
HRBC carrier in sera assayed against TNP-HRBC. The ME-resistant HA titers are 7S IgG 
(18, 19) while the ME sensitive titers, as determined by subtracting the 7S titer from the total 
titer,  represent the 19S IgM titers (20, 21). 
RESULTS 
E2fecl of Trealrnenl  with TXBS.--The  injection of TNBS results in a state of 
immunological tolerance that is specific for the TNP hapten. This was demon- 
strated by treating groups of mice with TNBS (5 mg in saline) and challenging 
with  an intraperitoneal  injection of 2  X  10  s TNP-SRBC  after an  appropriate 
interval. Fig. 1 and Table I show the results obtained with a 1 h interval between 
TNBS treatment  and  hapten-carrier  challenge.  No anti-TNP  serum  antibody 
nor PFC  response  was  obtained. The anticarrier  SRBC response was normal. 
FIG.  1.  Effect of TNBS treatment upon the anti-TNP serum antibody response to TNP- 
SRBC. Anti-TNP HA titer of treated (upper graph) and untreated control (lower graph) mice. 
Treated mice received 5.0 mg of TNBS in 0.5 ml of saline at  -  l  h. All mice were challenged 
with 2  X  l0 s TNP-SRBC i.p. on days 0 and 29 as indicated.  19S  (0)  and 7S  (O)  anti-TNP 
antibody HA titers were determined as described in Materials and Methods. Titers are from 
a  pool of serum from five mice per group.  Abscissa: days after initial TNP-SRBC  challenge 
injection; ordinate: log., anti-TNP  HA titer. 
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TABLE I 
t~l~ect of T:VBS  Treatment upon the Immune Response to TNP-SRBC 
Treatment  Anti-TNP PFC/106  Anti-SRBC PFC/10~ 
TNBS* 
--1 hr  0  4- 0§  120.2  4-  20§ 
None:~  49.8  4-  5.2  127.8  4-  10.9 
* An i.p. injection of 5.0 mg of TNBS in 0.5 mI of saline was given 1 h  before an i.p. 
challenge injection of 2 )< 108 TNP-SRBC. 
No treatment other than challenge with 2 X  108 TNP-SRBC was given. 
§ Values represent the mean of five mice per group  +  SE. Mice were assayed 5 days after 
challenge. 
In addition to having no effect upon the anticarrier responses, TNBS had no 
significant effect upon  the serum  antibody or PFC  response  to unconjugated 
SRBC since the serum antibody' and PFC response to SRBC in TNBS-treated 
and untreated mice was the same. Similarly, treatment of mice with TNBS from 
1 to 4 day's before an injection 9f SRBC had no effect upon the anti-SRBC re- 
sponse  (data not shown).  Furthermore,  the injection of TNBS  did  not  result 
in detectable PFC to TNP 5 days later, indicating that TNBS is purely tolero- 
genic. 
Effect of Concentration of TNBS  on the Induction of Tolerance to TNP-SRBC. 
---In  order  to  further  characterize  the  tolerogenic  effects  of  TNBS,  a  dose- 
response  experiment was  conducted.  Groups  of 5-10  mice  were  treated  with 
doses of TNBS ranging from 0.1 to 10 mg in 0.5 ml of saline. The control group 
received saline. 2  days later a  cha!lenge injection of 2  X  l0  s TNP-SRBC  was 
given, and  the anti-TNP  and anti-SRBC PFC  responses were assayed 5  days 
later. As seen in Fig. 2,  a  control level anti-TNP response was obtained in the 
group receiving 0.1 mg of TNBS. As the dose of TNBS was increased, the anti- 
hapten  response decreased until 0.4 =t= 0.2 and 0  PFC/106 were obtained with 
5  and  10  mg  of  TNBS,  respectively.  The  anticarrier  SRBC  responses  were 
slightly reduced in comparison to the control at the three highest doses, 2.5, 5, 
and 10 mg of TNBS. It appears, therefore, that 5 mg is an appropriate dose of 
TNBS  for use in the induction of tolerance to TNP,  while having little effect 
upon  control  anticarrier  responses  and  eliciting no  antibody  response  itself. 
There was high mortality in the group receiving 10 mg of TNBS  (80%), while 
no mortality was observed in the remaining groups during this and succeeding 
experiments. 
Effect of Chemical Nature of TNP Moiety upon Tolerance Induction.--In  order 
to investigate the role played by chemical reactivity of the tolerogen in tolerance 
to  TNP,  groups  of  mice  were  treated  with  various  compounds  in  amounts 
equimolar in the TNP moiety with the standard 5 mg TNBS dose. A  challenge 
injection of 2  )<  l0  s TNP-SRBC  was given 2  days later, and  the direct PFC 46  INDUCTION  OE  TOLERANCE  TO  TNP 
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FIG. 2.  Dose-response effect of TNBS upon the PFC response to TNP-SRBC. Anti-TNP 
(I) and anti-SRBC (O) PFC response of mice treated with various doses of TNBS ranging 
from 0  (control) to 10.0 mg. Mice were challenged with an i.p. injection of 2 X  l0  s TNP- 
SRBC 2 days after TNBS treatment,  and were assayed for PFC 5 days later,  Values rep- 
resent the mean PFC response of five mice per group -4- SE with  the  exception of group  F 
(receiving 10 mg of TNBS), which is the response of  the  lone survivor. The anti-TNP re- 
sponses of groups E and F were 0.4 4- 0.2  and 0, respectively. Abscissa: treatment of mice; 
ordinate: anti-TNP and anti-SRBC PFC/106 responses. 
response was assayed 5 days later. The results are shown in Table II. As pre- 
viously  demonstrated,  TNBS  treatment  induces  tolerance  to  TNP.  TNP- 
glycine did not reduce the response to either hapten or carrier. The response of 
mice  receiving  1,3,5-TNB  was  reduced  compared  with  the  control  group; 
however, giving TNP in this free but nonreactive form did not result in  toler- 
ance induction. It  appears,  therefore,  that  the  virtue of  TNBS  being a  free 
hapten is not sufficient to induce tolerance to TNP, and that the reactivity of 
file SO:~- group may be the necessary feature. 
D~4,ration of TNBS-l,zduced Tolerauce.--In order to investigate the extent and 
duration of TNBS-induced tolerance to TNP, groups of 5-30 mice were treated 
with TNBS followed by a challenge injection of 2  X  10  s TNP-SRBC after an 
appropriate interval. The responses to hapten and carrier were assayed 5 days 
later. The results are  shown in Fig. 3  a.  With the shortest intervals between 
TNBS treatment and hapten-carrier challenge (< 1 day), complete tolerance to 
"FNP was obtained, and the anticarrier SRBC responses were at control levels. 
As the interval between tolerogen and hapten-carrier challenge was lengthened 
the anti-TNP response increased gradually. By 1 mo, the antihapten response 
had risen to  approximately the control level. It is apparent that tolerance to 
TNP induced by TNBS treatment is of finite duration, is hapten specific, and 
does not affect the anticarrier response. 
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TABLE  II 
Effect of Reactivity and "Free" Form of Hapten in the Induction  of Tolerance to TNP* 
Group and treatment 
TNP  SRBC 
PFC/10  6  PFC/spleen  PFC/10 6  PFC/spleen 
A 
TNBS  0.1~  -4- 0.1  12  ±  10  77  ±  18  6,834  ±  1,907 
B 
TNP-glycine  33  ±  12  2,384  ±  740  161  ±  39  11,532  ±  2,323 
C 
1,3,5-TNB§ in  8  ±  1  646  ±  122  93  ±  14  7,800  ±  1,541 
1% Na2SO3 
D 
1% Na2SO3  351I  3,150  201  18,060 
E 
Control  16  ±  3  1,840  4-  201  103  ±  7  10,758  ±  1,476 
* Groups of five mice were treated with a variety of materials containing the TNP moiety. 
Treatment was an i.p. injection of 0.5 rnl of saline containing an amount of material equi- 
molar with the standard 5 mg dose of TNBS in terms of the TNP moiety. 
:~ Values represent  the  mean day 5 PFC/106  or PFC/spleen response against TNP or 
SRBC of five mice per group ±  SE. 
§ l% Na2SO~ in saline was used as the diluent for 1,3,5-TNB because of solubility diffi- 
culties. 
I] Values for group D represent the responses of a pool of five spleens. 
upon an ongoing immune response to TNP-SRBC was investigated. Groups of 
5-16 mice were challenged with an injection of 2 )<  108 TNP-SRBC followed by 
the standard dose of TNBS after an interval of 1 h to 4 days. The PFC responses 
to hapten and carrier were determined 5 days after the TNP-SRBC immuniza- 
tion. These results are presented in Fig. 3 b. Tolerance to TNP was produced in 
mice given TNBS  1  h  to 3 day's after hapten-carrier challenge. With a 4 day 
interval between immunogen and  tolerogen, however,  a  significant anti-TNP 
PFC response was observed. In this case, TNBS was given 24 h before the PFC 
assay, indicating that TNBS does not mask the immune response to the hapten 
by binding to PFC. Thus TNBS can induce specific tolerance to TNP in mice 
which are in the induction phase of the response to a hapten-carrier conjugate 
without altering the ant±carrier response. 
Effect of Secondary Injection of Haplen-Carrier in TNBS-Toleranl  Animals.- 
The effect of TNBS  treatment before a  primary challenge of TNP-SRBC on 
the  response  to  a  subsequent injection of  h~pten-carrier  was  investigated. 
Groups of five to nine mice were given 5 rag of TNBS in 0.5 ml of saline followed 
after an interval of from 1 h to 14 days by a primary challenge injection of TNP- 
SRBC. All mice received a  second injection of TNP-SRBC 28 days later and 
were assayed 4 days later for both direct and indirect PFC (see Materials and 
Methods). The results are shown in Figs. 4 a  and 5 a. Essentially control-level 48  INDUCTION  O1:" TOLERANCE  TO  TNP 
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FIG. 3. Duration of TNBS-induced tolerance. Anti-TNP (11) and anti-SRBC (e) PFC re- 
sponse of mice treated with 5.0 mg of TNBS in 0.5 ml of saline at a wide variety of intervals 
(a) ranging from 1 h to 42 days before or (b) ranging from 1 h to 4 days after an i.p. challenge 
injection of 2 X l0  s TNP-SRBC. PFC were determined 5 days later.  Values represent  the 
mean of the PFC response of 5-30 mice 4- SE. The horizontal shaded bars represent the SE 
range (mean 4- SE) of the anti-SRBC  (upper bar) and anti-TNP (lower bar)  responses of 
(a) 31 or (b)  16 untreated  control mice to a challenge injection of 2 X 10  s TNP-SRBC.  (a) 
and (b) were run as two separate experimental procedures. Abscissa: time before TNP-SRBC 
challenge that TNBS  treatment was given; ordinate:  anti-TNP and anti-SRBC  PFC/106 
responses. 
direct  and  indirect  secondary anticarrier responses  were  obtained but  there 
were no indirect anti-TNP PFC in response to the secondary injection of hap- 
ten-carrier conjugate. The direct antihapten response was very low (<5 PFC), 
less than the control direct responses. 
The secondary response of mice given TNBS  after  the  initial TNP-SRBC 
challenge was investigated. Groups of seven to nine mice were imnmnized with 
2  X  10  s TNP-SRBC and given TNBS after an interval of 12,  24,  or 48 h. All 
mice  received a  secondary challenge of TNP-SRBC  28  days  after  the  initial 
injection, and were assayed for the PFC  response to TNP and SRBC  4  days 
later. As seen in Figs. 4 b and 5 b, tolerance to TNP x~as observed in all treated 
groups, while the anticarrier responses were at control levels. Thus, similar to 
TNBS treatment before the initiation of the primary response, treatment after 
the initiation  of a primary response results in tolerance to a secondary challenge 
given 28 days later. 
It is important to note that  the  antihapten responses of treated mice to a 
secondary injection of hapten-carrier conjugate are  in some cases lower than 
the primary response of similarly treated mice (compare groups given TNBS 
with intervals before primary TNP-SRBC challenge of 6,  8,  and 14 days be- JOHN  M.  FIDLER  AND  EDWARD  S.  GOLUB  49 
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FIc.  4.  Effect of TNBS upon the anti-SRBC PFC response to a  secondary challenge with 
TNP-SRBC.  Anti-SRBC  PFC  response of mice treated with TNBS  at a variety of interva]s 
ranging from  (a)  1 h  to  14 days before or  (b)  12-48 h  after a  primary injection of 2  X  l0 s 
TNP-SRBC.  28  days later a  second injection of TNP-SRBC  was given, and the secondary 
response was assayed 4  days thereaftei.  Values represent the mean of the anti-SRBC PFC 
response of 5-9 mice 4- SE.  Open figures represent direct PFC  responses, and closed figures 
are indirect PFC  responses. The horizontal shaded  bars represent the control direct  (lower) 
and indirect (upper) PFC responses. Abscissa: time after TNBS treatment that 2  X  l0 s TNP- 
SRBC primary challenge injection was given; ordinate: anti-SRBC PFC/106 responses. 
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FIO.  5.  Effect of TNBS upon the anti-TNP response to a  secondary challenge with TNP- 
SRBC. For details, see legend for Fig. 4. 50  INDUCTION  OF  TOLERANCE  TO  TNP 
tween Figs. 3  and 4). Apparently, mice which were in the process of escaping 
from tolerance when initially challenged had been induced to reenter the tol- 
erant state by the TNP-SRBC  challenge and this apparent state of tolerance 
persisted through the 28 day secondary hapten-carrier challenge. This seems to 
be the case even where a significant antihapten response to the initial challenge 
was obtained. 
Reentry into the Tolerant State by Mice Escaping from Tolerance.--In order to 
test more precisely the possibility that animals escaping from tolerance could be 
induced to reenter the tolerant state, the following experiment was conducted. 
Groups of 10  mice were given TNBS injections  (5.0 mg in 0.5  ml of saline). 
One-half of the mice in each group were given a  challenge injection  of TNP- 
SRBC  at an interval after TNBS treatment that varied with the group (2-14 
days). All mice were challenged with TNP-SRBC 28 days after the day of the 
initial  challenge.  A  primary response  assay,  (direct  PFC)  was  conducted  on 
those mice receiving only one hapten-carrier injection,  while  a  secondary re- 
sponse assay (indirect PFC)  was performed on the mice having received two 
injections.  The  data  from this  experiment are  summarized in Table III. By 
comparing those mice treated with TNBS at the same interval it is apparent 
that there is a decrease in the anti-TNP responsiveness of TNBS treated mice 
given  a  day 0  hapten-carrier challenge.  It  appears  that  the  initial  challenge 
injection  of TNP-SRBC resulted in  the induction  of a  longer-lasting state of 
tolerance. 
DISCUSSION 
The experiments reported here show that treatment of mice with a nonim- 
munogenic preparation of free reactive hapten leads to the induction of a state 
of tolerance to the hapten.  This is determined by the lack of response to the 
haptenic moiety when  administered as an immunogenic hapten-carrier conju- 
gate.  The  tolerance produced is  specific for the hapten,  since  the  anticarrier 
responses  are  essentially unaltered.  The unresponsiveness induced  by TNBS 
treatment is a  dose-dependent  phenomenon becoming less complete with low 
doses of tolerogen. The tolerance is of a definite  length both in the induction 
phase and in the duration of the established unresponsive state.  Tolerance can 
be maintained and extended both by hapten-carrier  challenge and by the ad- 
ministration of additional tolerogen, and may be reentered once escape has been 
initiated. 
TNBS is a purely tolerogenic form of the  TNP moiety, apparently owing its 
tolerogenicity at least partially to the presence of a reactive sulfonic  acid group 
which  binds  in  vitro  to  lysine  groups  of proteins.  The  tolerance  induced  by 
TNBS is hapten (TNP)-specific, and is observed not only at the serum antibody 
level, where antigen  could conceivably remove antibody from the circulation, 
but also at the cellular level (PFC). Serum antibody and PFC responses to the 
carrier are unaffected by the tolerization by TNBS. However, in a later paper,  ~ JOHN  M.  FIDLER  AND  EDWARD  S.  GOLUB 
TABLE  III 
Effect of Antigen Challenge on Tolerance Induction* 
51 
Group 
IA 
B 
II  A 
B 
III  A 
B 
IV A 
B 
VA 
B 
VI A 
B 
TNBS 
interval 
+ 
4 
4  + 
6 
6  + 
8 
8  + 
1 
14 
14  + 
Control 
Control  + 
[~  Anti-TNP 
.~8§  Drl 
27"*q -  6 
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26  ± 
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23  ± 
+  2.5:t= 
+  38  ± 
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I¶ 
0.7  4-  0.4 
10  184 
1.2  0.6  ±  0.4  5.5 
4  174 
1.5  0.5  4-  0.2  12 
6  134 
1.3  1.0  ±  0.5  7.3 
7  120 
1.3  0.3  4-  0.3  3.5 
8  126 
2  47  4-  9  8.4 
Anti-SRBC 
DH 
196"'4-  31 
5.9  4-  0.9 
PFC/10  6 
i¶ 
185  4-  52 
4-  31 
4-  1.5  176  ±  33 
4-5 
4-  3  142  ±  31 
4-  30 
4-  1.4  194  4-  18 
±  28 
±  2.3  113  ±  49 
4-  10 
4-  1.4  208  4-  36 
* TNBS  (5.0 mg in 0.5 ml of saline) was given followed in an intelval of from 2-14 days 
by a  challenge to one-half of each group of 2  X  108 TNP-SRBC.  All mice were challenged 
with 2  X  108 TNP-SRBC 28 days later. Mice receiving one injection of hapten-carrier were 
assayed for a  primary response and those receiving two injections were given a  secondary 
response assay. 
The interval between  TNBS  and  the  initial injection of  hapten-carrier. Control mice 
received no TNBS. 
§ +,  2  X  108 TNP-SRBC  injection given on the day indicated;  --,  no injection given 
on the day indicated. 
][ D-direct PFC/106 response. 
¶ I-indirect PFC/108 response (see Materials and Methods). 
** Values represent the mean of five mice 4- SE. 
we will show that thymus-derived cells from TNBS-tolerant  animals can reduce 
the ant±carrier response under certain experimental conditions. 
It is unlikely  that  masking  of PFC  by TNBS  is responsible for  the lack  of 
TNP-specific  PFC.  When  TNBS  was  given on day 4  after TNP-SRBC  chal- 
lenge,  a  significant response was obtained,  while shorter intervals (from 1 h  to 
3  days)  resulted  in complete  tolerance  to  TNP.  This shows  that  tolerance  to 
TNP  may  be induced during the induction phase of the antibody response and 
also presumably  while the antibody response is in progress, i.e.,  on  day  3.  The 
result with a  4  day interval indicates that  after a  certain point in the response 
PFC  have been generated which cannot be tolerized or blocked by TNBS. 
The injection of TNBS  could result in the trinitrophenylation of serum pro- 52  INDUCTION  OF  TOLERANCE  TO  TNP 
teins, which are retained in the circulation for several days after the treatment. 
Additionally,  within  1 h  after treatment,  TNBS  or conjugation products are 
being excreted in the urine.  It is very unlikely that TNBS in the free, native 
form makes contact with more than  the few antigen-sensitive cells which  are 
presumably present in the peritoneal cavity. Affinity labeling is therefore not 
likely to be the mode of action of the tolerogen. It is possible that, in conjugating 
to various constituents of serum and peritoneal fluid, a situation similar to that 
investigated  by Havas  (5)  and  Borel  (6)  exists.  Rather  than  conjugation  of 
serum proteins in vitro, haptenation  takes place in  vivo. Serum from TNBS- 
treated mice contains both trinitrophenylated albumins and globulins (unpub- 
lished observations). Neither treatment of spleen cells with TNP serum (serum 
on day 1 after TNBS  treatment)  in vitro followed by adoptive transfer to le- 
thally X-irradiated recipients nor pretreatment of intact mice with TNP serum 
had  any effect upon  the  response to a  subsequent  TNP-SRBC  challenge.  Of 
course, variables such as haptenation  ratios and possible  alterations in serum 
constitution cannot be controlled in vivo as with in vitro conjugation. 
In addition to trinitrophenylation of serum constituents, mouse erythrocytes 
taken from mice 1 day after standard TNBS treatment were found by HA titra- 
tion of a  standard  reference anti-TNP antiserum to be conjugated with TNP 
.(unpublished  observation). The injection  of these  cells or in  vitro heavily or 
lightly  conjugated  TNP-mouse erythrocytes  into  syngeneic or  allogeneic  re- 
cipients failed to induce tolerance? 
The response to certain antigens is dependent upon cellular cooperation be- 
tween thymus-derived antigen-reactive cells (T cells) and thymus-independent 
bone marrow-derived antigen-sensitive cells (B cells). The mechanism of coop- 
eration is still unclear.  According to the cell interaction model of humoral im- 
munity, tolerance in either the B  or T  cell population or both will result in a 
state of systemic tolerance  in  the  animal in question.  In the cell cooperation 
theory of hapten-carrier immunity, carrier-specific T cells aid the hapten-specific 
B cells in some manner in the production of antihapten antibody. In such a case, 
tolerance in either cell type would also lead to a state of tolerance to the hapten. 
Using HGG, Chiller et al. (22)  have demonstrated tolerance in both the B and 
T  cell lines,  with T  ceils entering  tolerance more quickly,  at  a  lower dose of 
tolerogen, and for a much longer duration  than the B  cell line.  In the TNBS- 
TNP system there is reason to believe that tolerance is induced in the hapten- 
specific B cell line.  4 Presumably, the long-lasting antihapten tolerance in delayed 
hypersensitivity (23)  is due to unresponsiveness at the T  cell  level. It is likely 
that TNBS induces tolerance in the T cell line as well as the B cell line. If toler- 
ance is induced in the TNP-specific T  cell line, the differences in humoral anti- 
TNP responsiveness would  be virtually undetectable  according to the model. 
This is so because  the  T  ceils specific for the  carrier  (SRBC)  would  fulfill a 
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carrier-specific function and aid the hapten-specific B  cells  in  the response to 
TNP. Essentially, therefore,  according to the hapten-carrier theory of cell co- 
operation only tolerance in the hapten-specific B cell line  would be detectaMe 
using a hapten-carrier system of humoral immunity. Tolerance in the hapten- 
specific T cell line would be masked by the cooperative efforts of the carrier-spe- 
cific T  cells. However, a T  cell inhibitor substance may be induced by TNBS? 
The state of tolerance to TNP induced by TNBS treatment is of limited dura- 
tion.  Escape from TNBS-induced tolerance can be postponed by a  challenge 
with  a  hapten-carrier conjugate which under normal circumstances would be 
optimal for the induction of immunity. This extension and in some cases rever- 
sion  to the  tolerant state  after a  significant level  of responsiveness had  been 
regained is dependent upon the protocol of maintenance challenges in terms of 
duration and characteristics of the escape phenomenon and will be the subject 
of the next paper in this series. G 
SUMMARY 
Treatment  of  mice  with  a  nonimmunogenic  preparation  of  free  reactive 
hapten,  trinitrobenzene  sulfonic  acid  (TNBS),  leads  to  the  induction  of  a 
state  of tolerance  to  the  hapten,  2,4,6-trinitrophenyl  (TNP).  This is  deter- 
mined  by  the  lack  of  response  to  the  haptenic  moiety in  an  immunogenic 
hapten-carrier  conjugate  (TNP-SRBC)  as  assayed  both  bv  serum  antibody 
titrations  and  the hemolytic plaque  assay. The tolerance produced is specific 
for the  hapten,  since the  anticarrier  responses  are  essentially unaltered  com- 
pared with the control values. The unresponsiveness induced by TNBS treat- 
ment is a dose-dependent phenomenon, becoming less complete at lower doses 
of TNBS. The tolerance is of a definite length, both in its induction phase and 
in the duration of the established unresponsive state.  Tolerance can be main- 
tained  and  extended,  and  may  also  be  reentered  once  escape  has  been  ini- 
tiated. 
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